Tremfya (guselkumab) emerges as a groundbreaking treatment for ulcerative colitis, offering hope for symptom management through its dual-acting interleukin-23 inhibitory action. Understanding its dosing schedule, eligibility criteria.
Eligibility and Precautions
Tremfya is not recommended for patients with active infections or those undergoing concurrent treatment with another biologic or targeted synthetic therapy, reinforcing the need for careful patient assessment and monitoring. Essential before commencing the therapy
Treatment Safety and Considerations
Tremfya boasts a well-documented safety profile. Common side effects include respiratory tract infections and reactions at the injection site, which occur more frequently than with placebo treatments. Patients are advised to report any prolonged side effects to their healthcare providers